Amova Asset Management Americas Inc. Sells 72,555 Shares of Personalis, Inc. $PSNL

Amova Asset Management Americas Inc. lessened its position in shares of Personalis, Inc. (NASDAQ:PSNL) by 12.3% in the fourth quarter, Holdings Channel.com reports. The firm owned 518,441 shares of the company’s stock after selling 72,555 shares during the period. Amova Asset Management Americas Inc.’s holdings in Personalis were worth $4,127,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Kennedy Capital Management LLC boosted its stake in shares of Personalis by 196.2% during the 3rd quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after buying an additional 1,281,695 shares during the last quarter. Aberdeen Group plc boosted its stake in shares of Personalis by 36.1% during the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after buying an additional 861,948 shares during the last quarter. ARK Investment Management LLC boosted its stake in shares of Personalis by 11.3% during the 3rd quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock worth $51,574,000 after buying an additional 802,268 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Personalis by 1,172.0% in the 2nd quarter. Ameriprise Financial Inc. now owns 329,865 shares of the company’s stock valued at $2,164,000 after purchasing an additional 303,933 shares during the last quarter. Finally, Nano Cap New Millennium Growth Fund L P acquired a new stake in Personalis in the 4th quarter valued at about $2,308,000. Institutional investors own 61.91% of the company’s stock.

Insider Activity at Personalis

In other Personalis news, CEO Christopher M. Hall sold 80,091 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $11.02, for a total transaction of $882,602.82. Following the completion of the sale, the chief executive officer directly owned 235,986 shares in the company, valued at $2,600,565.72. This trade represents a 25.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $12.01, for a total transaction of $480,400.00. Following the sale, the chief financial officer owned 198,833 shares of the company’s stock, valued at $2,387,984.33. This trade represents a 16.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 178,799 shares of company stock valued at $2,031,692 over the last 90 days. Company insiders own 4.20% of the company’s stock.

Wall Street Analysts Forecast Growth

PSNL has been the subject of several recent analyst reports. BTIG Research cut their target price on shares of Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, May 11th. Needham & Company LLC raised their target price on shares of Personalis from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Morgan Stanley cut their target price on shares of Personalis from $10.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Finally, Wall Street Zen upgraded shares of Personalis from a “sell” rating to a “hold” rating in a research note on Saturday, May 30th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $11.00.

Personalis Stock Down 1.4%

Shares of PSNL stock opened at $9.61 on Thursday. The firm has a 50 day moving average price of $7.42 and a two-hundred day moving average price of $8.25. The company has a market capitalization of $1.01 billion, a PE ratio of -9.42 and a beta of 2.28. Personalis, Inc. has a 12-month low of $3.84 and a 12-month high of $12.53.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The company had revenue of $15.47 million for the quarter, compared to analyst estimates of $14.49 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. As a group, research analysts expect that Personalis, Inc. will post -1.06 EPS for the current year.

Personalis Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.